MedTrace Logo

A Phase I Trial of LY3143921 Hydrate in Solid Tumours

NCT03096054 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 69

Last updated 2026-08-18

No results posted yet for this study

Summary

This clinical study looked at a drug called LY3143921 hydrate (a Cdc7 inhibitor) in adult patients with advanced solid tumours. The main aims were to find out the maximum dose of LY3143921 hydrate that could be given safely to patients, and to assess the potential side effects and how they could be treated.

Conditions

Interventions

DRUG

LY3143921 hydrate

LY3143921 hydrate was administered orally on a daily schedule. Each cycle of treatment consisted of 21 days, and patients may have initially received up to 12 cycles. If the patient was benefitting, they may have continued beyond 12 cycles.

Sponsors & Collaborators

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-21
Primary Completion
2025-04-09
Completion
2025-04-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03096054 on ClinicalTrials.gov